Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma?

[1]  A. Nicholson,et al.  The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. , 2021, Pathology.

[2]  S. Tamiya,et al.  Development of mesothelioma in situ and its progression to invasive disease observed in a patient with uncontrolled pleural effusions for 15 years , 2020, Pathology international.

[3]  L. Bubendorf,et al.  Putative Malignant Pleural Mesothelioma in situ (MPMIS) with Sequential Acquisition of Genomic Alterations on Fluorescence in situ Hybridization (FISH) Examination , 2020, Acta Cytologica.

[4]  Y. Maniwa,et al.  Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report , 2019, Virchows Archiv.

[5]  F. Galateau-Sallé,et al.  Malignant mesothelioma in situ: morphologic features and clinical outcome , 2019, Modern Pathology.

[6]  S. Dacic,et al.  Malignant mesothelioma in situ , 2018, Histopathology.

[7]  K. Nabeshima,et al.  Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma. , 2016, Lung cancer.

[8]  A. Gown,et al.  Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. , 2013, Archives of pathology & laboratory medicine.

[9]  F. Galateau-Sallé,et al.  The Separation of Benign and Malignant Mesothelial Proliferations , 2000, Archives of pathology & laboratory medicine.

[10]  F. Galateau-Sallé,et al.  Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas , 2008, Virchows Archiv.

[11]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[12]  M. Ladanyi,et al.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  D. Henderson,et al.  The concept of mesothelioma in situ: implications for diagnosis and histogenesis. , 1992, Seminars in diagnostic pathology.

[14]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.